We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Drug Company To Pay $55M To Settle Federal Securities Fraud Claims

Mealey's (May 9, 2016, 2:29 PM EDT) -- NEW YORK — A drug company will pay $55 million to shareholders to settle claims that it failed to disclose adverse clinical trial results for its nonalcoholic steatohepatitis drug, obeticholic acid...
To view the full article, register now.